The shadow of generic competition has repeatedly loomed above copyright’s iconic drug, Sildenafil, sparking questions about the future of related pharmaceutical holdings. While initial times saw significant profits, the patent expiration has opened the door for cheaper alternatives, potentially reducing earnings and presenting a genuine danger fo